Physician profile
Chengping Wang
NPI 1710537063
$10,510.29
in general payments reported to CMS, 2019-2025
16 companies · $2,641 in 2025
The $2,641 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,182 · 2022: $1,730 · 2023: $2,399 · 2024: $2,558 · 2025: $2,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,561 · Education: $36.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,560.73 |
| Education | $36.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,737.08 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,567.76 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,322.17 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $1,017.58 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $959.11 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $903.75 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $766.82 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $695.48 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $608.30 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $403.79 | 2024-2025 | Cobenfy |
| Eisai INC. | $217.47 | 2021-2022 | |
| Corium, LLC | $122.06 | 2023 | Azstarys |
| Acadia Pharmaceuticals INC | $113.96 | 2022 | |
| Ironshore Pharmaceuticals INC. | $34.10 | 2023 | Jornay Pm |
| Indivior INC. | $20.97 | 2024 | Sublocade |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $19.89 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chengping Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.